Anil Verma, MD
Cardiovascular Disease · Cincinnati, OHNPI 1669521365
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $25,652 of the $33,293 with a category attached, or 77.0%. It is spread thinly across 48 manufacturers, the largest accounting for just 16.8% — the pattern of someone who eats at a lot of different presentations. Among cardiovascular disease clinicians in OH with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 695 payments — averaging $47.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Penumbra, Inc.$6K
- Boston Scientific$5K
- Imperative Care, Inc$4K
- Abbott$4K
- Inari Medical, Inc.$2K
- Abiomed$2K
- plus $10K from 42 others
Across 52 payments — averaging $3117.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Cardiovascular Systems Inc.$90K
- Penumbra, Inc.$41K
- Abbott$17K
- Boston Scientific$9K
- EKOS Corporation$5K
What the payments were for
- Consulting fees$1,0003%
- Speaking & faculty fees$4,80014%
- Travel & lodging$1,8416%
- Food & beverage$25,65277%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Indigo$5,394
- WATCHMAN Access System$1,784
- FLOWTRIEVER CATHETER, S$1,356
- Impella$1,252
- EKOSONIC$1,019
- ZOOM 88-T LARGE DISTAL PLATFORM$1,000
- CT THROMBECTOMY SYSTEM KIT$996
- Watchman$928
- TRICLIP$883
- SYMPHONY CATHETER$828
- PRODIGY CATHETER$773
- XACT$622
- SAPIEN 3 Ultra RESILIA$376
- Vascular Lithotripsy$360
- LifeSPARC$280
- Absolute Pro vascular stent system$280
- Diamondback Peripheral$257
- Supera peripheral stent system$252
- NEXLIZET$247
- NEXLETOL$247
How this compares
$33,293 in reported general payments places this provider in the 90th percentile of 827 cardiovascular disease providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 165 | $181,723 |
| XareltoRivaroxaban | 49 | $70,205 |
| EntrestoSacubitril/Valsartan | 45 | $63,996 |
| FarxigaDapagliflozin Propanediol | 31 | $35,831 |
| BrilintaTicagrelor | 55 | $31,809 |
| JardianceEmpagliflozin | 28 | $27,391 |
| ClopidogrelClopidogrel Bisulfate | 502 | $3,485 |
| Ranolazine ErRanolazine | 18 | $2,514 |
| Atorvastatin Calcium | 295 | $1,866 |
| Metoprolol Succinate | 173 | $1,573 |
| Torsemide | 87 | $1,379 |
| Amiodarone Hcl | 42 | $1,143 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 20 | $934 |
| Rosuvastatin Calcium | 90 | $762 |
| Carvedilol | 98 | $679 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $221 | $181,723165 claims |
| Johnson & JohnsonXarelto | $1,095 | $70,20549 claims |
| AstraZenecaFarxiga, Brilinta | $46 | $67,64086 claims |
| NovartisEntresto | $1,263 | $63,99645 claims |
| Boehringer IngelheimJardiance | $154 | $27,39128 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 827 cardiovascular disease providers in Ohio.
Other cardiovascular disease in Cincinnati
- Kamal ShemisaCincinnati$314K
- Richard BaeCincinnati$136K
- Dylan SteenCincinnati$91K
- Joel FormanCincinnati$64K
- Freidoon GhaziCincinnati$56K
- Wojciech MazurCincinnati$44K
- Guilherme AttizzaniCleveland$1.3M
- Gregory LamCircleville$428K
- Emil HayekHudson$379K
- Abraham LincoffCleveland$369K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.